BenevolentAI, a clinical-stage AI drug discovery company, went public via a SPAC merger with Odyssey Acquisition in a $1.7bn deal. The transaction includes a c.$152m PIPE from Temasek, AstraZeneca, Ally Bridge Group and Invus. "The combination with Odyssey will allow us to scale our vision and ambition of uniting purposeful technology and cutting-edge science to discover life-changing medicines," Joanna Shields, BenevolentAI CEO.